Search research articles

Search research articles

Related Experiment Videos

A simulation study using validated prognostic factors to assess expected long-term survival.

M Pfirrmann¹, J Hasford

¹IBE Institut für Medizinische Informatik, Biometrie und Epidemiologie, Ludwig-Maximilians-Universität, München, Germany. pfi@ibe.med.uni-muenchen.de

Methods of Information in Medicine

|December 14, 2005

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Comprehensive molecular characterization of treatment-free remission and molecular relapse in chronic myeloid leukemia patients: the EURO-SKI Biomarker Study.

Leukemia·2026

Same author

The JAK1/2 inhibitor ruxolitinib in patients with COVID-19 triggered hyperinflammation: the RuxCoFlam trial.

Leukemia·2023

Same author

A patient-centred web-based adverse drug reaction reporting system identifies not yet labelled potential safety issues.

European journal of clinical pharmacology·2021

Same author

Regional deep hyperthermia: quantitative evaluation of predicted and direct measured temperature distributions in patients with high-risk extremity soft-tissue sarcoma.

International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group·2019

Same author

Diagnostic value of cerebrospinal fluid CXCL13 for acute Lyme neuroborreliosis. A systematic review and meta-analysis.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2018

Same author

Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML.

Leukemia·2018

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

This study simulated long-term survival for imatinib in chronic myeloid leukemia (CML). Imatinib demonstrated a significant survival advantage over interferon-alpha, particularly for patients achieving major cytogenetic remission (MCR).

Area of Science:

Hematology
Oncology
Clinical Trials

Background:

Long-term survival data for imatinib in chronic myeloid leukemia (CML) is crucial, especially compared to interferon-alpha.
Many patients on interferon-alpha in clinical trials have switched to imatinib, limiting direct comparative data.
A simulation study is needed to estimate imatinib's long-term survival benefits.

Purpose of the Study:

To estimate the long-term survival advantage of imatinib treatment in chronic myeloid leukemia (CML).
To compare simulated imatinib survival data with historical interferon-alpha treatment outcomes.
To utilize prognostic factors from interferon-alpha treatment for imatinib survival prediction.

Main Methods:

Survival probabilities for interferon-alpha treated patients with and without major cytogenetic remission (MCR) were analyzed.

Related Experiment Videos

Simulated survival data for imatinib-treated patients (intermediate and low-risk) were generated.

Simulations involved drawing varying percentages of survival times from interferon-alpha MCR and non-MCR groups.

Main Results:

10-year survival for interferon-alpha: 0.22 (intermediate-risk) and 0.37 (low-risk).
Simulated 10-year survival with imatinib showed significant increases: 0.43-0.57 (80% MCR-like), 0.36-0.49 (65% MCR-like), 0.30-0.42 (50% MCR-like).
Survival probabilities increased in all simulation scenarios for imatinib.

Conclusions:

Imatinib is predicted to offer a survival advantage in chronic myeloid leukemia (CML) compared to interferon-alpha.
Even with conservative assumptions about MCR, imatinib showed improved survival.
These findings support the observed benefits of imatinib as treatment duration increases.